Related Experiment Video
Updated: Jun 14, 2026

09:39
Creation of Reversible Cholestatic Rat Model
Published on: May 22, 2011
Choleretic effect of valproic acid in the rat
Hepatology (Baltimore, Md.)
|July 1, 1981
Summary
Valproic acid (VPA) effectively increases bile flow in rats, acting as a choleretic agent. This effect is dose-dependent and primarily driven by the osmotic activity of VPA metabolites in bile.
Area of Science:
- Pharmacology
- Hepatology
- Gastroenterology
Background:
- Valproic acid (VPA) is a widely used anticonvulsant.
- Its effects on bile production (choleresis) are not fully understood.
- Investigating VPA's impact on bile flow is crucial for understanding its physiological effects.
Purpose of the Study:
- To investigate the choleretic effect of Valproic acid (VPA) in rats.
- To determine the origin and mechanism of VPA-induced choleresis.
- To assess the dose-dependency and duration of VPA's effect on bile flow.
Main Methods:
- Intravenous administration of VPA to male Sprague-Dawley rats at varying doses.
- Measurement of bile flow rate, bile composition (bile acids, ions, cholesterol, phospholipids), and VPA concentrations in bile, plasma, and liver.
- Assessment of VPA's impact on bile salt-independent flow and biliary excretion of other compounds.
Main Results:
- VPA significantly increased bile flow rate in a dose-dependent manner.
- The increased bile flow was of canalicular origin and primarily stimulated bile salt-independent flow.
- VPA metabolites, particularly glucuronides, were found in bile, contributing to choleresis via osmotic activity.
- VPA enhanced inorganic ion excretion, potentially contributing to the choleretic effect.
Conclusions:
- Valproic acid is an effective choleretic agent in rats.
- VPA-induced choleresis originates from the canalicular system.
- The primary mechanism involves the osmotic activity of VPA conjugates in bile, enhancing bile salt-independent flow.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

